

## Zafgen Inc

### COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 26-Apr-2015

#### THOMSON REUTERS

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



## ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



**PLEASE NOTE:** the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Company Financials..... 8

Product Portfolio Summary..... 13

Product Portfolio Drugs..... 17

[Return to Table of Contents](#)

# Zafgen Inc

## COMPANY OVERVIEW

|                                       |  |
|---------------------------------------|--|
| Company Name                          | Zafgen Inc   |
| Parent Company Name                   | Zafgen Inc   |
| Website                               | <a href="http://www.zafgen.com/">http://www.zafgen.com/</a>  |
| Country                               | US   |
| Number of Drugs in Active Development | 3  |
| Number of Inactive Drugs              | 3  |
| Number of Patents as Owner            | 33   |
| Number of Patents as Third Party      | 0  |
| Number of Deals                       | 3  |
| Key Indications                       | Obesity, Non-insulin dependent diabetes, Non-alcoholic steatohepatitis, Brain tumor, Non alcoholic fatty liver disease, Prader-Willi syndrome, Weight gain, Weight loss, Alzheimers disease, Angiogenesis disorder, Cardiovascular disease, Stroke |
| Key Target-based Actions              | Methionine aminopeptidase-2 inhibitor, C-reactive protein inhibitor, Thioredoxin stimulator, Methionine aminopeptidase-2 modulator   |
| Key Technologies                      | Small molecule therapeutic, Oral formulation, Subcutaneous formulation, Natural product, Crystalline form, Intravenous formulation, Formulation preservation, Oligonucleotide antisense  |

## COMPANY PROFILE

### SUMMARY

Zafgen, founded in 2005, is a private venture-backed biopharmaceutical company that develops obesity therapeutics based on vascular targeting in adipose tissue.

### COMPANY LOCATION

The company is based in Cambridge, MA.

### LICENSING AGREEMENTS

In January 2009, Argenta Discovery and Zafgen signed an agreement to research and discover therapeutics for the treatment of obesity.

In August 2008, Anthill and Zafgen entered into an agreement where Anthill was to use its ACOS high-speed synthesis and purification capabilities to assist Zafgen in lead compounds identification for its obesity programs.

### FINANCIAL

In January 2015, the company commenced an underwritten public offering of 2,840,909 shares of its common stock. The underwriters were to be granted a 30-day option to purchase up to an additional 426,136 shares of common stock. Later that month, Zafgen priced the offering of 3,942,200 common stock shares at a price of \$35 each, which includes the underwriters' option to purchase up to an additional 514,200 common stock shares at the public offering price. The offering was expected to close on or about January 28, 2015. Later that month, the offering was closed.

In December 2014, Zafgen was selected for addition to the NASDAQ Biotechnology Index.

In June 2014, Zafgen announced an IPO of 6,000,000 shares of its common stock priced at \$16 per share. At that time, underwriters were granted a 30-day option to purchase up to an additional 900,000 shares of common stock to cover any over-allotments. The shares were traded on the NASDAQ Global Market under the ticker symbol "ZFGN". Later that month, the offering was closed and at that time, the over-allotment option was fully exercised.

In April 2014, the company closed \$20 million term loan with Oxford Finance LLC and MidCap Financial.

[Return to Table of Contents](#)



In December 2013, Zafgen raised \$45 million in a series E equity financing round.

In December 2012, Zafgen raised \$21 million in a series D equity financing.

In July 2011, Zafgen raised \$33 million in a series C financing.

COMPANY FINANCIALS

SHARE INFORMATION

|                                      |                   |
|--------------------------------------|-------------------|
| Close Price (USD)                    | 39.90             |
| Change (USD)                         | -0.62 (-1.53%)    |
| Previous Close Price (USD)           | 40.52             |
| Volume                               | 345,173           |
| 52-Week High (USD)                   | 55.36             |
| 52-Week Low (USD)                    | 16.01             |
| Date                                 | 24-Apr-2015       |
| Exchange                             | NASDAQ(COMPOSITE) |
| Current Number of Shares Outstanding | 26,856,329        |
| Current Market Capitalization        | 1,071,567,527     |
| EPS (Date Reported)                  | -3.00021          |

[Return to Table of Contents](#)

## STOCK PERFORMANCE



## MAJOR SHAREHOLDERS


| Shareholder                                       | Type               | Country       | Shares held | % of shares held | Change in holding | % changes in shares held | Date        |
|---|--------------------|---------------|-------------|------------------|-------------------|--------------------------|-------------|
| Fidelity Select Biotechnology Portfolio           | Mutual Fund        | United States | 2,613,501   | 9.73             | 342,801           | 0.15                     | 28-Feb-2015 |
| Fidelity Advisor Biotechnology Fund               | Mutual Fund        | United States | 1,306,751   | 4.87             | 171,402           | 0.15                     | 28-Feb-2015 |
| SPDR S&P Biotech ETF                              | Mutual Fund        | United States | 518,760     | 1.93             | 518,760           | 1                        | 31-Mar-2015 |
| Franklin Templeton Invest-Biotechnology Discovery | Mutual Fund        | United States | 467,158     | 1.74             | -5,488            | -0.01                    | 31-Jan-2015 |
| Granahan Investment Management, Inc.              | Investment Advisor | United States | 327,727     | 1.22             | 219,597           | 2.03                     | 31-Mar-2015 |
| iShares NASDAQ Biotechnology ETF                  | Mutual Fund        | United States | 326,433     | 1.22             | 60,885            | 0.23                     | 31-Mar-2015 |
| Vanguard Total Stock Market Index Fund            | Mutual Fund        | United States | 187,677     | 0.7              | 20,930            | 0.13                     | 31-Mar-2015 |
| BlackRock Health Sciences Opportunities Portfolio | Mutual Fund        | United States | 176,500     | 0.66             | 176,500           | 1                        | 28-Feb-2015 |

[Return to Table of Contents](#)



|  |                               |               |         |      |         |      |             |
|--|-------------------------------|---------------|---------|------|---------|------|-------------|
| Prudential Jennison Health Sciences Fund     | Mutual Fund                   | United States | 153,985 | 0.57 | 0       | 0    | 28-Feb-2015 |
| Loomis, Sayles & Company, L.P.               | Investment Advisor/Hedge Fund | United States | 141,234 | 0.53 | 141,234 | 1    | 28-Feb-2015 |
| Loomis Sayles Small Cap Growth Fund          | Mutual Fund                   | United States | 141,234 | 0.53 | 141,234 | 1    | 28-Feb-2015 |
| iShares Russell 2000 ETF                     | Mutual Fund                   | United States | 137,286 | 0.51 | 18,314  | 0.15 | 31-Mar-2015 |
| Vanguard Extended Market Index Fund          | Mutual Fund                   | United States | 115,347 | 0.43 | 102,047 | 7.67 | 28-Feb-2015 |
| Prudential Jennison Small Company Fund, Inc. | Mutual Fund                   | United States | 102,589 | 0.38 | 102,589 | 1    | 28-Feb-2015 |
| Starr (Kevin P)                              | Individual Investor           | United States | 81,345  | 0.3  | 73,237  | 9.03 | 24-Mar-2015 |
| Hamilton Lane Advisors, LLC                  | Private Equity                | United States | 74,941  | 0.28 | 74,941  | 1    | 31-Mar-2015 |
| iShares Russell 2000 Growth ETF              | Mutual Fund                   | United States | 55,895  | 0.21 | 10,786  | 0.24 | 31-Mar-2015 |
| Forward Growth Fund                          | Mutual Fund                   | United States | 55,000  | 0.2  | 20,000  | 0.57 | 28-Feb-2015 |
| Fidelity Spartan Extended Market Index Fund  | Mutual Fund                   | United States | 47,420  | 0.18 | 27,058  | 1.33 | 28-Feb-2015 |
| AST Small-Cap Growth Opportunities Portfolio | Mutual Fund                   | United States | 47,320  | 0.18 | 47,320  | 1    | 28-Feb-2015 |

[Return to Table of Contents](#)



|                          | 2011    | 2012    | 2013    | 2014    |  |
|--------------------------|---------|---------|---------|---------|--|
| Sales (USD M)            | 0       | 0       | 0       | 0       |  |
| Operating Income (USD M) | -13.154 | -13.791 | -13.78  | -35.532 |  |
| Net Income (USD M)       | -13.157 | -13.88  | -14.027 | -36.478 |  |

[Return to Table of Contents](#)

## Quarterly earnings update

| Period  | Sales (USD M) | Operating Income (USD M) | Net Income (USD M) |
|---------|---------------|--------------------------|--------------------|
| 2014 Q4 | 0             | -10.664                  | -10.931            |
| 2014 Q3 | 0             | -14.361                  | -14.689            |
| 2014 Q2 | 0             | -5.986                   | -6.443             |
| 2014 Q1 | 0             | -4.521                   | -4.507             |
| 2013 Q4 | 0             | -3.761                   | -3.899             |
| 2013 Q3 | 0             | -3.524                   | -3.557             |
| 2013 Q2 | 0             | -2.975                   | -3.19              |
| 2013 Q1 | 0             | -3.52                    | -3.594             |
| 2012 Q4 | 0             | -3.006                   | -3.086             |

## BALANCE SHEET

### Assets (USD M)

|                                     | 2012   | 2013   | 2014    |  |  |
|-------------------------------------|--------|--------|---------|--|--|
| Cash & Short Term Investments       | 9.935  | 35.517 | 115.462 |  |  |
| Inventories - Total                 | 0      | 0      | 0       |  |  |
| Current Assets - Total              | 10.324 | 37.358 | 117.198 |  |  |
| Property, Plant And Equipment - Net | 0.032  | 0.037  | 0.079   |  |  |
| Other Assets - Total                | 0.63   | 0.743  | 0.242   |  |  |
| Total Assets                        | 10.986 | 38.138 | 117.519 |  |  |

### Liabilities (USD M)

|   | 2012  | 2013  | 2014   |  |  |
|---|-------|-------|--------|--|--|
| Accounts Payable                                    | 1.231 | 2.015 | 2.348  |  |  |
| Short Term Debt & Current Portion Of Long Term Debt | 0     | 0     | 1.381  |  |  |
| Current Liabilities - Total                         | 2.93  | 2.915 | 6.901  |  |  |
| Long Term Debt                                      | 0     | 0     | 6.177  |  |  |
| Other Liabilities                                   | 0     | 0     | 0      |  |  |
| Total Liabilities                                   | 2.93  | 2.915 | 13.078 |  |  |

[Return to Table of Contents](#)

## Stockholders Equity (USD M)

|  | 2012   | 2013    | 2014    |  |  |
|--|--------|---------|---------|--|--|
| Minority Interest                        | 0      | 0       | 0       |  |  |
| Preferred Stock                          | 62.785 | 103.797 | 0       |  |  |
| Common Stock                             | 0.005  | 0.005   | 0.023   |  |  |
| Treasury Stock                           | 0      | 0       |         |  |  |
| Total Liabilities & Shareholders' Equity | 10.986 | 38.138  | 117.519 |  |  |

## FORECASTS

### EPS Forecast

| Year ending | Current Forecast | 1 month ago | 3 months ago |
|-------------|------------------|-------------|--------------|
| 31-Dec-2015 | -3.12            | -2.36       | -2.673       |
| 31-Dec-2016 | -3               | -2.34       | -3.084       |
| 31-Dec-2017 | -2.68            | -2.44       | -3.542       |

### Other Forecasts

| Year ending | DPS | CPS | Pretax | Sales |
|-------------|-----|-----|--------|-------|
| 31-Dec-2015 |     |     | -81.03 | 0     |
| 31-Dec-2016 |     |     | -89.47 | 0     |
| 31-Dec-2017 |     |     | -85.8  | 7.4   |


[Return to Table of Contents](#)

## PRODUCT PORTFOLIO SUMMARY

### DRUGS

#### Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

Drugs by Indication Table

| Indication               | Active | Inactive | Total |
|--------------------------|--------|----------|-------|
| Nutritional disorder     | 3      | 3        | 6     |
| Gastrointestinal disease | 2      | 1        | 3     |
| Metabolic disorder       | 2      | 1        | 3     |
| Endocrine disease        | 2      | 1        | 3     |
| Inflammatory disease     | 1      | 0        | 1     |
| Neoplasm                 | 1      | 0        | 1     |
| Neurological disease     | 1      | 0        | 1     |

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

| Development Status      | Number of Drugs |
|-------------------------|-----------------|
| Phase 3 Clinical        | 1               |
| Discovery               | 2               |
| No Development Reported | 3               |

[Return to Table of Contents](#)

## DEALS

| Deal Type                                    | Principal |          | Partner |          | Total |
|--|-----------|----------|---------|----------|-------|
|  | Active    | Inactive | Active  | Inactive |       |
| Drug - Early Research/Development            | 0         | 0        | 1       | 0        | 1     |
| Drug - Development/Commercialization License | 0         | 0        | 1       | 0        | 1     |
| Technology - Target Validation               | 0         | 0        | 1       | 0        | 1     |

## CLINICAL TRIALS

### Trials by Condition Studied

| Condition Studied        | Ongoing | All |
|--------------------------|---------|-----|
| Nutritional disorder     | 2       | 8   |
| Metabolic disorder       | 1       | 1   |
| Endocrine disease        | 1       | 1   |
| Gastrointestinal disease | 1       | 1   |

### Trials by Phase

| Phase   | Ongoing | All |
|---------|---------|-----|
| Phase 3 | 1       | 1   |
| Phase 2 | 1       | 4   |
| Phase 1 | 0       | 3   |

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

| Indication               | As Owner | As Third Party | Total |
|--------------------------|----------|----------------|-------|
| Cardiovascular disease   | 7        | 0              | 7     |
| Endocrine disease        | 4        | 0              | 4     |
| Gastrointestinal disease | 5        | 0              | 5     |
| Genitourinary disease    | 4        | 0              | 4     |

[Return to Table of Contents](#)



|                           |    |   |    |
|---------------------------|----|---|----|
| Growth disorder           | 1  | 0 | 1  |
| Hematological disease     | 1  | 0 | 1  |
| Degeneration              | 3  | 0 | 3  |
| Andrology                 | 1  | 0 | 1  |
| Immune disorder           | 1  | 0 | 1  |
| Psychiatric disorder      | 2  | 0 | 2  |
| Musculoskeletal disease   | 4  | 0 | 4  |
| Neoplasm                  | 2  | 0 | 2  |
| Ocular disease            | 1  | 0 | 1  |
| Genetic disorder          | 1  | 0 | 1  |
| Metabolic disorder        | 6  | 0 | 6  |
| Mouth disease             | 1  | 0 | 1  |
| Neurological disease      | 4  | 0 | 4  |
| Nutritional disorder      | 25 | 0 | 25 |
| Respiratory disease       | 1  | 0 | 1  |
| Infectious disease        | 2  | 0 | 2  |
| Injury                    | 2  | 0 | 2  |
| Inflammatory disease      | 3  | 0 | 3  |
| Fatigue                   | 1  | 0 | 1  |
| Gynecology and obstetrics | 1  | 0 | 1  |
| Dermatological disease    | 1  | 0 | 1  |

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)



## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### beloranib (sc, obesity/Prader-Willi syndrome/craniopharyngioma ), Zafgen

|                             |   |
|-----------------------------|---|
| <b>Drug Name</b>            | beloranib (sc, obesity/Prader-Willi syndrome/craniopharyngioma ), Zafgen    |
| <b>Key Synonyms</b>         | beloranib   |
| <b>Originator Company</b>   | Chong Kun Dang Pharmaceutical Corp  |
| <b>Active Companies</b>     | Zafgen Inc  |
| <b>Inactive Companies</b>   | Chong Kun Dang Pharmaceutical Corp  |
| <b>Highest Status</b>       | Phase 3 Clinical  |
| <b>Active Indications</b>   | Obesity, Brain tumor, Prader-Willi syndrome, Non-insulin dependent diabetes |
| <b>Target-based Actions</b> | Methionine aminopeptidase-2 inhibitor                                       |
| <b>Other Actions</b>        | Hypoglycemic agent, Lipid metabolism modulator, Anticancer                  |
| <b>Technologies</b>         | Subcutaneous formulation, Small molecule therapeutic                        |
| <b>Last Change Date</b>     | 20-Apr-2015   |

### ZGN-839

|                             |   |
|-----------------------------|---|
| <b>Drug Name</b>            | ZGN-839   |
| <b>Key Synonyms</b>         |   |
| <b>Originator Company</b>   | Zafgen Inc  |
| <b>Active Companies</b>     | Zafgen Inc  |
| <b>Inactive Companies</b>   |   |
| <b>Highest Status</b>       | Discovery   |
| <b>Active Indications</b>   | Non-insulin dependent diabetes, Non alcoholic fatty liver disease, Non-alcoholic steatohepatitis, Obesity |
| <b>Target-based Actions</b> | Methionine aminopeptidase-2 inhibitor   |
| <b>Other Actions</b>        | Hypoglycemic agent, Anti-inflammatory   |
| <b>Technologies</b>         | Oral formulation, Small molecule therapeutic  |
| <b>Last Change Date</b>     | 20-Mar-2015   |

[Return to Table of Contents](#)

second generation beloranib (obesity), Zafgen

|                      |  |
|----------------------|--|
| Drug Name            | second generation beloranib (obesity), Zafgen        |
| Key Synonyms         | beloranib  |
| Originator Company   | Zafgen Inc   |
| Active Companies     | Zafgen Inc   |
| Inactive Companies   |  |
| Highest Status       | Discovery  |
| Active Indications   | Obesity  |
| Target-based Actions | Methionine aminopeptidase-2 inhibitor                |
| Other Actions        |  |
| Technologies         | Subcutaneous formulation, Small molecule therapeutic |
| Last Change Date     | 20-Apr-2015  |

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)